Analyst
H.C. Wainwright
Equibles does not estimate personal net worth.
Raghuram Selvaraju is recorded as Analyst at H.C. Wainwright. Raghuram Selvaraju has spoken on 9 earnings calls and 1 other investor event across 8 companies, most recently for Fennec Pharmaceuticals Inc. on August 11, 2026. Those appearances were for UroGen Pharma Ltd. (URGN), Fennec Pharmaceuticals Inc. (FENC), Emergent BioSolutions Inc. (EBS), Rhythm Pharmaceuticals, Inc. (RYTM), Abeona Therapeutics Inc. (ABEO) and 3 other companies. The companies whose calls Raghuram Selvaraju spoke on are classified in the Healthcare and Consumer Defensive sectors.
“Firstly, I wanted to ask about what your outlook is with regard to the timeline with which you might be in a position to provide us with a revenue guidance range, if not for this year, then potentially for 2027.”
“Firstly, with respect to the Narcan situation, I was wondering if you could provide us with some additional granularity on any potential initiatives that you think are likely to be particularly effective in A, slowing the pace at which Narcan sales might erode, and B, potentially leverage the brand recognition that…”
“Thanks so much for taking our questions and congratulations on a highly impressive quarter.”
“Just with respect to Prader-Willi syndrome, given the extended history so far with at least one approved drug in that condition and greater familiarity overall with that target indication, can you share with us any additional information at this time regarding market segmentation analysis and what you anticipate to be…”
“Hello, everyone, and welcome to this next in a series of fireside chats here at the Wainwright BioConnect conference. My name is Ram Selvaraju, and I'm a managing director and senior health care equity research analyst here at H.C. Wainwright.”
H.C. Wainwright
Analyst
Source not stated
URGN
Biotechnology · Healthcare
Drug Manufacturers - Specialty & Generic · Healthcare
